The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: Combined meta-analysis of efficacy and safety profile - 03/04/15
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Purpose |
To investigate the efficiency and safety profile of the addition of S-1 to gemcitabine (GEM)-based chemotherapy for advanced pancreatic cancer (APC).
Methods |
Computerized search was undertaken to identify randomized controlled trials of S-1 plus GEM versus GEM monotherapy in APC patients. The outcomes included overall survival (OS), progression-free survival (PFS), response rate, and toxicities.
Results |
Five studies with 917 patients were included. Overall, there was a significant difference between the two regimens in terms of OS (HR=0.83, 95%CI=0.72–0.96, P=0.01), PFS (HR=0.64, 95%CI=0.56–0.74, P<0.0001), and overall response rate (ORR; RR=2.36, 95%CI=1.73–3.22, P<0.00001). Occurrence of grade 3/4 hematological toxicities (neutropenia, thrombocytopenia) and non-hematological toxicities (diarrhea, nausea/vomit, rush, stomatitis/mucositis) were significantly higher with GEM/S-1 treatment.
Conclusions |
This meta-analysis indicated a significant survival benefit with increased toxicity when S-1 was combined with GEM. GEM/S-1 might be an option of first-line chemotherapy for APC patients, at least in Asia.
Le texte complet de cet article est disponible en PDF.Abbreviations : CI, RR, HR
Plan
Vol 39 - N° 2
P. 254-260 - avril 2015 Retour au numéro
Article précédent
- Coffee consumption and risk of gastric cancer: An updated meta-analysis
- Zhiyong Shen, Hua liu, Hui Cao
- Subclinical hypothyroidism as an independent risk factor for colorectal neoplasm
- Guifang Mu, Xuefeng Mu, Huizhi Xing, Ruibiao Xu, Guangxi Sun, Chonghai Dong, Qichuan Pan, Chao Xu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?